These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1352 related articles for article (PubMed ID: 29357948)
1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Gong J; Chehrazi-Raffle A; Reddi S; Salgia R J Immunother Cancer; 2018 Jan; 6(1):8. PubMed ID: 29357948 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Akinleye A; Rasool Z J Hematol Oncol; 2019 Sep; 12(1):92. PubMed ID: 31488176 [TBL] [Abstract][Full Text] [Related]
5. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Bellmunt J; Powles T; Vogelzang NJ Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651 [TBL] [Abstract][Full Text] [Related]
6. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833 [TBL] [Abstract][Full Text] [Related]
8. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148 [TBL] [Abstract][Full Text] [Related]
9. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy. Fang XN; Fu LW Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881 [TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
11. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. Villaruz LC; Socinski MA Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296 [TBL] [Abstract][Full Text] [Related]
13. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
14. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Kopalli SR; Kang TB; Lee KH; Koppula S Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857 [TBL] [Abstract][Full Text] [Related]
16. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 blockade in renal cell cancer. Beckermann KE; Johnson DB; Sosman JA Expert Rev Clin Immunol; 2017 Jan; 13(1):77-84. PubMed ID: 27426025 [TBL] [Abstract][Full Text] [Related]
18. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Balar AV; Weber JS Cancer Immunol Immunother; 2017 May; 66(5):551-564. PubMed ID: 28213726 [TBL] [Abstract][Full Text] [Related]
19. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J Front Immunol; 2020; 11():563258. PubMed ID: 33488573 [TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Nishijima TF; Shachar SS; Nyrop KA; Muss HB Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]